Journal: Avicenna Journal of Medical Biotechnology

Article Title: The Anticancer Activity Compared Between Triptorelin and a New Gonadotropin Releasing Hormone Analogue

doi:

Figure Lengend Snippet: Effect of 6 days of treatment with different concentrations of triptorelin and the new analogue on OVCAR3 cell line. Each column represents the cell number percent in comparison with control. The data are representative of three independent experiments. Analysis of variance: P < 0.01

Article Snippet: Human breast cancer cell line (T47D) and ovarian cancer cell line (OVCAR3) were obtained from Pasteur Institute of Iran.

Techniques: Comparison, Control

Journal: Avicenna Journal of Medical Biotechnology

Article Title: The Anticancer Activity Compared Between Triptorelin and a New Gonadotropin Releasing Hormone Analogue

doi:

Figure Lengend Snippet: Cell number percent of cancer cell lines after treatment with (10 −11 , 10 −9 , 10 −7 , and 10 −5 M ) concentration of triptorelin and the new analogue

Article Snippet: Human breast cancer cell line (T47D) and ovarian cancer cell line (OVCAR3) were obtained from Pasteur Institute of Iran.

Techniques: Concentration Assay, Control

Journal: Avicenna Journal of Medical Biotechnology

Article Title: The Anticancer Activity Compared Between Triptorelin and a New Gonadotropin Releasing Hormone Analogue

doi:

Figure Lengend Snippet: (a) Normal OVCAR3 cell line. (b)Apoptotic forms of OVCAR3 cell line observed by invert phase-contrast microscope. Arrows show the morphologic signs of programmed cell death in early apoptosis

Article Snippet: Human breast cancer cell line (T47D) and ovarian cancer cell line (OVCAR3) were obtained from Pasteur Institute of Iran.

Techniques: Microscopy

Journal: Avicenna Journal of Medical Biotechnology

Article Title: The Anticancer Activity Compared Between Triptorelin and a New Gonadotropin Releasing Hormone Analogue

doi:

Figure Lengend Snippet: Apoptotic forms of OVCAR3 cell line observed by fluorescence microscope. OVCAR3 cell line was stained with annexinV-FITC/PI. Arrows show the plasma membrane asymmetry in early apoptotic cells. Boxes show different stage of apoptosis such as early and late / already dead cells

Article Snippet: Human breast cancer cell line (T47D) and ovarian cancer cell line (OVCAR3) were obtained from Pasteur Institute of Iran.

Techniques: Fluorescence, Microscopy, Staining, Clinical Proteomics, Membrane

Journal: Journal of Cancer

Article Title: Role of DEP domain-containing protein 1B (DEPDC1B) in epithelial ovarian cancer

doi: 10.7150/jca.78423

Figure Lengend Snippet: DEPDC1B promotes the proliferation of EOC cells. (A) Protein levels of DEPDC1B in human normal ovarian cell line IOSE-80, and the EOC cell lines OVCAR3 and SKOV3 were determined by western blot assays. (B) Efficiency of DEPDC1B upregulation was confirmed by western blot in stable DEPDC1B overexpression (DEPDC1B OE ) and control (DEPDC1B Ctrl ) OVCAR3 and SKOV3 cells. (C, D) Representative images from colony formation assay in DEPDC1B OE and DEPDC1B Ctrl OVCAR3 (C) and SKOV3 (D) cells. (E, F) EdU cell proliferation assay in DEPDC1B OE and DEPDC1B Ctrl OVCAR3 (E) and SKOV3 (F) cells. Data shown are the mean ± SEM of three independent experiments. * , P < 0.05, ** , P < 0.01.

Article Snippet: The EOC cell lines OVCAR3 and SKOV3, and the human hepatocellular carcinoma cell line BEL-7404 were obtained from Shanghai GeneChem Co., Ltd. (Shanghai, China).

Techniques: Western Blot, Over Expression, Colony Assay, Proliferation Assay

Journal: Journal of Cancer

Article Title: Role of DEP domain-containing protein 1B (DEPDC1B) in epithelial ovarian cancer

doi: 10.7150/jca.78423

Figure Lengend Snippet: DEPDC1B enhances AKT phosphorylation at Ser473 in EOC cells. (A, B) AKT and pAKT (S473) expression were analyzed by western blot in DEPDC1B OE and DEPDC1B Ctrl OVCAR3 (A) and SKOV3 (B) cells. The western blot is shown at the left, and densitometry result is shown at the right. Data shown are the mean ± SEM of three independent experiments. * , P < 0.05. (C) Western blot showing a reduction in pAkt at Ser473 on treatment with MK2206. The western blot is shown at the top, and densitometry result is shown at the bottom. Data shown are the mean ± SEM of three independent experiments. * , P < 0.05, ** , P < 0.01, *** , P < 0.001. (D) Western blot showing a reduction in pAkt at Ser473 on treatment with LY294002. The western blot is shown at the top, and densitometry result is shown at the bottom. Data shown are the mean ± SEM of three independent experiments. * , P < 0.05, ** , P < 0.01, *** , P < 0.001.

Article Snippet: The EOC cell lines OVCAR3 and SKOV3, and the human hepatocellular carcinoma cell line BEL-7404 were obtained from Shanghai GeneChem Co., Ltd. (Shanghai, China).

Techniques: Expressing, Western Blot

Journal: Journal of Cancer

Article Title: Role of DEP domain-containing protein 1B (DEPDC1B) in epithelial ovarian cancer

doi: 10.7150/jca.78423

Figure Lengend Snippet: DEPDC1B promotes the proliferation of EOC cells by enhancing AKT phosphorylation. (A) Colony formation assay shows reduction in the number of colonies on treatment with MK-2206 and LY294002 in DEPDC1B OE and DEPDC1B Ctrl OVCAR3 and SKOV3 cells. (B) EdU cell proliferation assay shows reduction in cell proliferation on treatment with MK-2206 and LY294002 in DEPDC1B OE and DEPDC1B Ctrl OVCAR3 and SKOV3 cells. Data shown are the mean ± SEM of three independent experiments. ** , P < 0.01, # , P > 0.05. (C) Protein levels of c-Myc in DEPDC1B OE and DEPDC1B Ctrl OVCAR3 and SKOV3 cells were determined by western blot assays. (D) Western blot showing a reduction in c-Myc expression on treatment with LY294002 in DEPDC1B OE and DEPDC1B Ctrl OVCAR3 and SKOV3 cells. (E) Western blot showing a reduction in c-Myc expression on treatment with MK2206 in DEPDC1B OE and DEPDC1B Ctrl OVCAR3 and SKOV3 cells.

Article Snippet: The EOC cell lines OVCAR3 and SKOV3, and the human hepatocellular carcinoma cell line BEL-7404 were obtained from Shanghai GeneChem Co., Ltd. (Shanghai, China).

Techniques: Colony Assay, Proliferation Assay, Western Blot, Expressing

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: SNCG promotes the progression and metastasis of high-grade serous ovarian cancer via targeting the PI3K/AKT signaling pathway

doi: 10.1186/s13046-020-01589-9

Figure Lengend Snippet: SNCG accelerates ovarian cancer cell proliferation, facilitates cell migration and invasion in vitro. a Western blot analysis of SNCG expression in different ovarian cancer cell lines. b The transfection efficiency was confirmed by Western blotting and qRT-PCR in SKOV3, HO-8901 PM, and OVCAR3 cells. c The MTT assay was used to detect ovarian cancer cell viability. d A soft agar assay was used to examine the proliferation of ovarian cancer cells. e Cell migration and invasion capabilities were determined using transwell assays (original magnification, × 200). f and g SKOV3 and HO-8910 PM cell transfectants were plated on FN and stained for SNCG, phalloidin, and nuclear. Moreover, cells were stained for Vimentin, MMP9, and F-actin. The individual or merged images visualized by a laser scanning confocal microscope (original magnification, × 1000). ▲ , P < 0.05. *, P < 0.001. Ctrl: control; Ove: overexpression; Scr: scramble; sh1: small hairpin RNA 1; sh2: small hairpin RNA 2; sh3: small hairpin RNA 3

Article Snippet: Human ovarian tumor cell lines SKOV3, OVCAR3, OVCAR5, ES-2 were purchased from Keygen Biotech (Jiang Su, China).

Techniques: Migration, In Vitro, Western Blot, Expressing, Transfection, Quantitative RT-PCR, MTT Assay, Soft Agar Assay, Staining, Microscopy, Control, Over Expression

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: SNCG promotes the progression and metastasis of high-grade serous ovarian cancer via targeting the PI3K/AKT signaling pathway

doi: 10.1186/s13046-020-01589-9

Figure Lengend Snippet: SNCG induces ovarian cancer progression via activating the PI3K/AKT signaling pathway. a-b A phospho-kinase array kit was performed on protein lysates of SKOV3-sh1 and control cells. Thirteen proteins were obvious changes in their phosphorylation status and highlighted by boxes. c Western blot analysis of the levels of Akt, p-Akt (Sec473), p70S6 kinase, p-p70S6 kinase (Thr389), mTOR, and p-mTOR (Sec2448) in SKOV3 and HO-8901 PM cells transfected with SNCG-shRNA or Scr, and OVCAR3 cells transfected with SNCG-Ove or Ctrl. d Expression levels of Akt, p-Akt (Sec473), p70S6 kinase, p-p70S6 kinase (Thr389), mTOR, and p-mTOR (Sec2448) in cells transfected with SNCG shRNA, Scr, SNCG Ove, Ctrl, IGF-1, and DMSO were determined by Western blot. e Expression levels of Akt, p-Akt (Sec473), p70S6 kinase, p-p70S6 kinase (Thr389), mTOR, and p-mTOR (Sec2448) in cells transfected with SNCG shRNA, Scr, SNCG Ove, Ctrl, LY294002, and DMSO were determined by Western blot. f Wound healing assay (upper, original magnification × 40) and cell colony formation (lower) of cells transfected with SNCG shRNA, Scr, SNCG Ove, Ctrl, IGF-1, LY294002, and DMSO confirmed the effect of SNCG on the PI3K/AKT signaling pathway. ▲ , P < 0.05. *, P < 0.001. IGF-1: insulin-like growth factor 1; sh-SNCG: small hairpin RNAs of SNCG

Article Snippet: Human ovarian tumor cell lines SKOV3, OVCAR3, OVCAR5, ES-2 were purchased from Keygen Biotech (Jiang Su, China).

Techniques: Control, Phospho-proteomics, Western Blot, Transfection, shRNA, Expressing, Wound Healing Assay